GlaxoSmithKline Pharmaceuticals has informed the stock exchanges of a scheduled analyst and institutional investor meeting, pursuant to Regulation 30 read with para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was filed on May 7, 2026, and signed by Ajay Nadkarni, Vice President – Administration, Real Estate & Company Secretary.

Meeting Details

The company has scheduled a group digital interaction with investors and analysts. The key details of the meeting are as follows:

Disclosure and Compliance

As per the company's communication, only information already available in the public domain will be shared during the interaction with investors and analysts. This disclosure is in line with SEBI's listing obligations, which require listed companies to inform exchanges in advance of scheduled analyst or institutional investor meetings.

The company has also noted that the scheduled date is subject to change due to exigencies on the part of either the investors or the company.

GlaxoSmithKline Pharmaceuticals Limited has formally notified stock exchanges about an upcoming board meeting scheduled for May 13, 2026. The pharmaceutical company issued the intimation on April 22, 2026, in compliance with regulatory requirements under the Listing Obligations and Disclosure Requirements Regulations, 2015.

Board Meeting Details

The meeting agenda encompasses several critical corporate matters that require board approval and consideration.

Key Agenda Items

The board will deliberate on multiple significant matters during the scheduled session:

• Financial Results Approval: Review and approval of audited financial results for both standalone and consolidated statements
• Quarterly and Annual Performance: Assessment of financial performance for the quarter and full year ended March 31, 2026
• Dividend Consideration: Evaluation and potential recommendation of dividend distribution to equity shareholders

Regulatory Compliance

The notification demonstrates GlaxoSmithKline Pharmaceuticals' adherence to mandatory disclosure requirements. The company has fulfilled its obligation under Regulations 29 and 33 of the LODR 2015, which mandate timely intimation to stock exchanges regarding board meetings that will consider financial results.

The formal communication was addressed to both BSE Limited and The National Stock Exchange of India Limited, ensuring comprehensive market notification. Company Secretary Ajay Nadkarni signed the official intimation, maintaining proper corporate governance protocols.

Corporate Information

GlaxoSmithKline Pharmaceuticals Limited operates from its corporate headquarters at GSK House, Dr. Annie Besant Road, Worli, Mumbai. The company maintains its corporate identity number as L24239MH1924PLC001151, reflecting its long-standing presence in the Indian pharmaceutical sector since 1924.